STAT+: An under-the-radar biotech finds FDA more receptive to an alternative to Covid vaccines
Written by
STAT News
Published
0
comments
0
min
Invivyd's CEO doesn’t want to see Covid vaccines disappear, but he does believe the monoclonal antibody candidate his company is developing can be an effective alternative.